{"url_path":"/sec/bmrn/8-k/2026-04-27/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1048477/0001193125-26-179243-index.html","accession_number":"0001193125-26-179243","cik":"0001048477","ticker":"BMRN","issuer_name":"BIOMARIN PHARMACEUTICAL INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1048477/0001193125-26-179243-index.html","primary_entity_key":"0001048477","primary_entity_name":"BIOMARIN PHARMACEUTICAL INC"},"word_count":294,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n \n\n(a)\n\nFinancial Statements of Businesses Acquired\n\nFinancial statements, to the extent required by this Item 9.01, will be filed by amendment to this Current Report on Form 8-K no later than 71 days following the date that this Current Report on Form 8-K is required to be filed.\n\n \n\n(b)\n\nPro Forma Financial Information\n\nFinancial statements, to the extent required by this Item 9.01, will be filed by amendment to this Current Report on Form 8-K no later than 71 days following the date that this Current Report on Form 8-K is required to be filed.\n\n \n\n(d)\n\nExhibits.\n\n \n\nExhibit\nNumber\n  \nDescription\n\n 2.1\n  \n[Agreement and Plan of Merger, dated as of December 19, 2025, by and among BioMarin Pharmaceutical Inc., Amicus Therapeutics, Inc. and Lynx Merger Sub 1, Inc. (incorporated by reference to Exhibit 2.1 to BioMarin’s Current Report on Form 8-K filed on December 19, 2025).](http://www.sec.gov/Archives/edgar/data/1048477/000119312525325856/d49247dex21.htm)\n\n 4.1\n  \n[Supplemental Indenture, dated as of April 27, 2026, by and among BioMarin Pharmaceutical Inc., certain guarantors party thereto, and U.S. Bank Trust Company, National Association.](d113922dex41.htm)\n\n10.1\n  \n[Credit Agreement, dated as of April 27, 2026, by and among BioMarin Pharmaceutical Inc., as the Borrower, Citibank, N.A., as administrative agent and collateral agent, and the lenders and issuing banks party thereto.](d113922dex101.htm)\n\n99.1\n  \n[Press Release issued by BioMarin Pharmaceutical Inc. on April 27, 2026.](d113922dex991.htm)\n\n104\n  \nCover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\n \nBIOMARIN PHARMACEUTICAL INC.,\n\nDate: April 27, 2026\n \n\n \nBy:\n \n\n/s/ G. Eric Davis\n\n \n\n \n\n \nG. Eric Davis\n\n \n\n \n\n \nExecutive Vice President, Chief Legal Officer"}